The estimated Net Worth of Frazor Titus Iii Edmondson is at least $2.09 million dollars as of 16 August 2024. Mr Edmondson owns over 4,850 units of Zai Lab stock worth over $664,270 and over the last 4 years he sold ZLAB stock worth over $723,381. In addition, he makes $707,297 as Chief Legal Officer & Corp. Sec. at Zai Lab.
Mr has made over 13 trades of the Zai Lab stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 4,850 units of ZLAB stock worth $104,615 on 16 August 2024.
The largest trade he's ever made was exercising 17,548 units of Zai Lab stock on 1 January 2024 worth over $378,510. On average, Mr trades about 6,007 units every 51 days since 2021. As of 16 August 2024 he still owns at least 30,796 units of Zai Lab stock.
You can see the complete history of Mr Edmondson stock trades at the bottom of the page.
Frazor Titus Edmondson III is the Chief Legal Officer & Corp. Sec. at Zai Lab.
As the Chief Legal Officer & Corp. Sec. of Zai Lab, the total compensation of Mr III at Zai Lab is $707,297. There are 1 executives at Zai Lab getting paid more, with Dr. Ying Du having the highest compensation of $1,376,036.
Mr III is 55, he's been the Chief Legal Officer & Corp. Sec. of Zai Lab since . There are 11 older and 9 younger executives at Zai Lab. The oldest executive at Zai Lab Limited is John Diekman, 77, who is the Independent Director.
Frazor's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Zai Lab have traded over $44,173,112 worth of Zai Lab stock and bought 19,000 units worth $666,380 . The most active insiders traders include Ying Du, William Lis et John D Diekman. On average, Zai Lab executives and independent directors trade stock every 14 days with the average trade being worth of $432,845. The most recent stock trade was executed by Richard Gaynor on 3 September 2024, trading 2,500 units of ZLAB stock currently worth $48,750.
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
Zai Lab executives and other stock owners filed with the SEC include: